Aurinia Pharmaceuticals (AUPH) EBITDA Margin (2019 - 2026)
Aurinia Pharmaceuticals' (AUPH) quarterly EBITDA Margin came in at 53.31% in Q1 2026, up 1833.0% YoY from 2.76% in Q1 2025, and up 23.67% on a QoQ basis from 43.1% in Q4 2025.
Aurinia Pharmaceuticals (AUPH) EBITDA Margin (2019 - 2026) Analysis & Trends
Aurinia Pharmaceuticals (AUPH) has 8 years of EBITDA Margin data on file, last reported at 53.31% in Q1 2026.
- Quarterly EBITDA Margin rose 1833.0% year-over-year to 53.31% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 41.73% (up 2944.0% YoY) and the FY2025 annual result came in at 37.06%, up 3906.0% from the prior year.
- EBITDA Margin advanced to 53.31% in Q1 2026, from 43.1% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 53.31% in Q1 2026 to a low of 175.18% in Q1 2022.
- A 5-year average of 26.66% and a median of 17.03% in 2022 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2022 — EBITDA Margin soared 535469 bps — and 2023, when it tumbled 1280 bps.
- Tracing AUPH's EBITDA Margin over 5 years: stood at 98.82% in 2022, then surged by 33 bps to 65.8% in 2023, then surged by 96 bps to 2.79% in 2024, then soared by 1646 bps to 43.1% in 2025, then gained by 24 bps to 53.31% in 2026.
- The last three EBITDA Margin figures came in at 53.31% (Q1 2026), 43.1% (Q4 2025), and 40.49% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Aurinia Pharmaceuticals | 2.06 Bn | 1.61 Bn | 76.67 Mn | 55.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 55.68% |
| Mar 31, 2026 | 53.31% |
| Dec 31, 2025 | 43.10% |
| Sep 30, 2025 | 40.49% |
| Jun 30, 2025 | 28.69% |
| Mar 31, 2025 | 34.97% |
| Dec 31, 2024 | -2.79% |
| Sep 30, 2024 | 17.33% |
| Jun 30, 2024 | -2.65% |
| Mar 31, 2024 | -26.35% |
| Dec 31, 2023 | -65.80% |
| Sep 30, 2023 | -29.83% |
| Jun 30, 2023 | -38.97% |
| Mar 31, 2023 | -85.98% |
| Dec 31, 2022 | -98.82% |
| Sep 30, 2022 | -17.03% |
| Jun 30, 2022 | -127.66% |
| Mar 31, 2022 | -175.18% |
| Dec 31, 2021 | -139.74% |
| Sep 30, 2021 | -343.31% |